Eton Pharmaceuticals, Inc. Increase (Decrease) in Accounts Receivable
Eton Pharmaceuticals, Inc. (ETON) reported Increase (Decrease) in Accounts Receivable of $13.13 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-08-13
- Eton Pharmaceuticals, Inc. increase (decrease) in accounts receivable for the quarter ending 2026-06-30 was $11.48M.
- Eton Pharmaceuticals, Inc. increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was $1.65M, a 85.04% decline year-over-year.
- Eton Pharmaceuticals, Inc. increase (decrease) in accounts receivable for the quarter ending 2025-12-31 was -$1.32M, a 241.11% decline year-over-year.
- Eton Pharmaceuticals, Inc. increase (decrease) in accounts receivable for the quarter ending 2025-09-30 was -$1.37M, a 291.21% decline year-over-year.
- Eton Pharmaceuticals, Inc. increase (decrease) in accounts receivable for fiscal 2025 was $6.40M, a 105.13% increase from fiscal 2024.
- Eton Pharmaceuticals, Inc. increase (decrease) in accounts receivable for fiscal 2024 was $3.12M, a 100.00% increase from fiscal 2023.
- Eton Pharmaceuticals, Inc. increase (decrease) in accounts receivable for fiscal 2023 was $1.56M.
- Eton Pharmaceuticals, Inc. increase (decrease) in accounts receivable for fiscal 2022 was -$3.62M, a 166.73% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $11.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $13.13M 10-Q · filed 2026-08-13 | $11.80M derived: sum of 3 quarters · filed 2026-08-13 | $10.43M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $1.65M 10-Q · filed 2026-05-14 | $326.00K derived: sum of 2 quarters · filed 2026-05-14 | -$1.04M derived: sum of 3 quarters · filed 2026-05-14 | -$2.99M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$1.32M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$2.70M derived: sum of 2 quarters · filed 2026-03-19 | -$4.64M derived: sum of 3 quarters · filed 2026-08-13 | $6.40M 10-K · filed 2026-03-19 |
| 2025-09-30 | -$1.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$3.32M derived: sum of 2 quarters · filed 2026-08-13 | $7.72M 10-Q · filed 2025-11-06 | $8.66M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$1.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $9.09M 10-Q · filed 2026-08-13 | $10.03M derived: sum of 3 quarters · filed 2026-08-13 | $10.75M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $11.04M 10-Q · filed 2026-05-14 | $11.98M derived: sum of 2 quarters · filed 2026-05-14 | $12.70M derived: sum of 3 quarters · filed 2026-05-14 | $13.33M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $939.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $1.66M derived: sum of 2 quarters · filed 2026-03-19 | $2.29M derived: sum of 3 quarters · filed 2026-03-19 | $3.12M 10-K · filed 2026-03-19 |
| 2024-09-30 | $717.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $1.35M derived: sum of 2 quarters · filed 2025-11-06 | $2.18M 10-Q · filed 2025-11-06 | $2.10M derived: sum of 4 quarters · filed 2026-03-19 |
| 2024-06-30 | $633.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $1.46M 10-Q · filed 2025-08-07 | $1.38M derived: sum of 3 quarters · filed 2026-03-19 | $1.79M derived: sum of 4 quarters · filed 2026-03-19 |
| 2024-03-31 | $829.00K 10-Q · filed 2025-05-13 | $745.00K derived: sum of 2 quarters · filed 2026-03-19 | $1.16M derived: sum of 3 quarters · filed 2026-03-19 | $1.37M derived: sum of 4 quarters · filed 2026-03-19 |
| 2023-12-31 | -$84.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $327.00K derived: sum of 2 quarters · filed 2026-03-19 | $537.00K derived: sum of 3 quarters · filed 2026-03-19 | $1.56M 10-K · filed 2026-03-19 |
| 2023-09-30 | $411.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $621.00K derived: sum of 2 quarters · filed 2024-11-12 | $1.64M 10-Q · filed 2024-11-12 | $2.00M derived: sum of 4 quarters · filed 2025-03-18 |
| 2023-06-30 | $210.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $1.23M 10-Q · filed 2024-08-08 | $1.59M derived: sum of 3 quarters · filed 2025-03-18 | $2.25M derived: sum of 4 quarters · filed 2025-03-18 |
| 2023-03-31 | $1.02M 10-Q · filed 2024-05-09 | $1.38M derived: sum of 2 quarters · filed 2025-03-18 | $2.04M derived: sum of 3 quarters · filed 2025-03-18 | $2.08M derived: sum of 4 quarters · filed 2025-03-18 |
| 2022-12-31 | $354.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $1.02M derived: sum of 2 quarters · filed 2025-03-18 | $1.06M derived: sum of 3 quarters · filed 2025-03-18 | -$3.62M 10-K · filed 2025-03-18 |
| 2022-09-30 | $664.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $702.00K derived: sum of 2 quarters · filed 2023-11-09 | -$3.97M 10-Q · filed 2023-11-09 | $1.11M derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-06-30 | $38.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$4.64M 10-Q · filed 2023-08-10 | $449.00K derived: sum of 3 quarters · filed 2024-03-14 | $531.00K derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-03-31 | -$4.67M 10-Q · filed 2023-05-11 | $411.00K derived: sum of 2 quarters · filed 2024-03-14 | $493.00K derived: sum of 3 quarters · filed 2024-03-14 | $496.00K derived: sum of 4 quarters · filed 2024-03-14 |
| 2021-12-31 | $5.09M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $5.17M derived: sum of 2 quarters · filed 2024-03-14 | $5.17M derived: sum of 3 quarters · filed 2024-03-14 | $5.42M 10-K · filed 2024-03-14 |
| 2021-09-30 | $82.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $85.00K derived: sum of 2 quarters · filed 2022-11-10 | $337.00K 10-Q · filed 2022-11-10 | $385.00K derived: sum of 4 quarters · filed 2023-03-16 |
| 2021-06-30 | $3.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $255.00K 10-Q · filed 2022-08-11 | $303.00K derived: sum of 3 quarters · filed 2023-03-16 | $303.00K derived: sum of 4 quarters · filed 2023-03-16 |
| 2021-03-31 | $252.00K 10-Q · filed 2022-05-12 | $300.00K derived: sum of 2 quarters · filed 2023-03-16 | $300.00K derived: sum of 3 quarters · filed 2023-03-16 | $95.00K derived: sum of 4 quarters · filed 2023-03-16 |
| 2020-12-31 | $48.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $48.00K derived: sum of 2 quarters · filed 2023-03-16 | -$157.00K derived: sum of 3 quarters · filed 2023-03-16 | -$425.00K 10-K · filed 2023-03-16 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-16 | -$205.00K derived: sum of 2 quarters · filed 2021-11-16 | -$473.00K 10-Q · filed 2021-11-16 | |
| 2020-06-30 | -$205.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | -$473.00K 10-Q · filed 2021-08-16 | ||
| 2020-03-31 | -$268.00K 10-Q · filed 2021-05-13 | |||
| 2019-12-31 | $473.00K 10-K · filed 2022-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |